Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention

Heart and Vessels

Volumn 23, Issue 1, 2008, Pages 35-39

  Kubota, Naozumi ^a   Kasai, Takatoshi ^a   Miyauchi, Katsumi ^a   Njaman, Widi ^a   Kajimoto, Kan ^a   Akimoto, Yoshinori ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aspirin; Long term outcome; Percutaneous coronary intervention; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NITRATE; PRAVASTATIN; THIAZIDE DIURETIC AGENT; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 39449095377     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-007-1007-8     Document Type: Article

References (18)

1. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamirozik K, Warlow C, Hafner B, Thompson E, Norton S (1988) Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 296:313-316
2. Final report on the aspirin component of the ongoing Physician's Health Study. Steering Committee of Physician's health study Research Group (1989) N Engl J Med 321:129-135
3. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speinzer FE, Hennekens CH (1991) A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 266:521-527
4. Fuster V, Dyken ML, Vokonas PS, Hennekens C (1993) Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation 87:659-675
5. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R (1989) Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80:749-756
6. Antiplatelet Trialists' Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed) 296:320-331
7. Matsuo T, Iwade K, Hirata N, Yamashita M, Ikegami H, Tanaka N, Aosaki M, Kasanuki H (2005) Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels 20(1):8-12
8. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA 287:3215-3222
9. Antithrombotic Trialists' Collaboration (2002) Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
10. Njaman WJ, Miyauchi K, Kasai T, Kurata T, Satoh H, Ohta H, Okazaki S, Yokoyama K, Kojima T, Akimoto Y, Daida H (2006) Impact of aspirin treatment on long-term outcome (over 10 years) after percutaneous coronary intervention. Int Heart J 47:37-45
11. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
12. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Event Trial investigators. N Engl J Med 335:1001-1009
13. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357
14. Hippisley-Cox J, Coupland C (2005) Effect of combination of drugs on all cause mortality in patients with ischemic heart disease; nested case-control analysis. BMJ 330:1059-1063
15. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonides AN, Kakafika AI, Daskalopulou SS, Elisaf M (2005) Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 16:65-71
16. Wascher TC (2003) Long-term statin safety and efficacy in secondary prevention can combination therapy improve outcomes? Atheroscler Suppl 14:11-16
17. Zhdanova IV, Tsvirenko SV, Barats SS, Smolenskaia OG, Volkova RF, Serezhenko TO (2002) Effect of fluvastatin and its combination with aspirin and trental on hemostasis and microcirculation in atherosclerosis. Ter Arkh 74:9-12
18. Ikonomidis I, Andreotti F (1999) Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100:793-798